重组人干扰素α2b联合洁悠神对宫颈持续HPV感染患者端粒酶与HPV16/18 E6蛋白表达的影响

Effect of rhIFN-α 2b combined with Jieyoushen on telomerase and HPV16/18 E6 protein expression in patients with cervical HPV infection

摘要:

目的对重组人干扰素α2b（rhIFN-α2b）联合洁悠神治疗宫颈持续HPV 感染的临床效果及其对端粒酶与HPV16/18 E6 蛋白表达的影响进行研究。方法随机选取2015 年1 月-2016年1 月于常州市第一人民医院进行治疗的宫颈持续人乳头瘤病毒（HPV）感染的108 例患者，按照数字随机表法分为观察组和对照组各54 例，对照组使用rhIFN-α2b 治疗，观察组在对照组的基础上使用洁悠神治疗。分别对两组患者的疗效、临床指标进行统计，并检测端粒酶与HPV16/18 E6 蛋白的表达水平。结果观察组治疗有效率与对照组比较，差异有统计学意义（χ2=5.240，P =0.022）；观察组患者治愈时间周、阴道排液时间以及出血时间与对照组比较，差异有统计学意义（t =3.485、4.765、4.365，P =0.001、0.000 和0.000），观察组均短于对照组；治疗后观察组的HPVDNA 负荷量低于对照组，并且转阴率与对照组比较，差异有统计学意义（χ2=6.546，P =0.000）；治疗后两组患者的端粒酶阳性率和HPV16/18 E6 蛋白阳性率均降低，差异有统计学意义（χ2=4.746、4.964，均P=0.000），其中观察组患者端粒酶阳性率和HPV16/18 E6 蛋白阳性率均低于对照组。结论联合使用rhIFN-α2b 和洁悠神治疗宫颈持续HPV 感染具有良好的治疗效果，可有效降低端粒酶和HPV16/18 E6 蛋白阳性率，并可降低患有宫颈癌的风险。

Abstract:

Objective To study the clinical effect of recombinant human interferon α 2b (rhIFN-α 2b) combined with Jieyoushen on cervical HPV infection, telomerase and expression of HPV16/18 E6 protein. Methods A total of 108 patients with cervical HPV infection who were treated in the First People's Hospital of Changzhou from January 2015 to January 2016 were selected. They were divided into observation group (54 cases) and control group (54 cases) according to the random number table method. The patients of the control group were treated with rhIFN-α 2b, and the patients of the observation group were treated with rhIFN-α 2b plus Jieyoushen. The efficacy and clinical indexes of the two groups were measured, and telomerase and HPV16/18 E6 protein expression were detected. Results The effective rate of the observation group was significantly higher than that of the control group(100.00% vs. 90.74%, P< 0.05). The cure time, vaginal excretion time and bleeding time [(7.04 ±1.68) w , (10.43±1.93) d and (12.47 ±1.56) d respectively] of the observation group were significantly shorter than those of the control group [(8.93 ±2.45) w, (14.58 ±2.76) d and (16.93 ±3.88) d;P < 0.05]. After treatment, the load of HPV DNA in the observation group was significantly lower than that in the control group, and the conversion rate was significantly higher than that in the control group (94.44% vs. 74.07%,P < 0.05). After treatment, the positive rates of telomerase and HPV16/18 E6 protein were significantly decreased in both groups, the positive rates of telomerase and HPV16/18 E6 protein in the observation group were significantly lower than those in the control group (1.85% vs. 11.11%, 3.70% vs. 14.81% respectively; < 0.05). Conclusions Combined use of rhIFN-α 2b and Jieyoushen has good therapeutic effect in the treatment of persistent HPV infection of cervix, can effectively reduce the positive rates of telomerase and HPV16/18 E6 protein, and reduce the risk of cervical cancer.